

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/540,234
				Filing Date	June 21, 2005
				First Named Inventor	Amanda Proudfoot
				Art Unit	Unknown 1647
				Examiner Name	unknown Ian Dang
Sheet	1	of	2	Attorney Docket Number	ARS-108

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/I.D./	U1	US- 5,739,103	04-14-1998	Rollins <i>et al.</i>	All
↓	U2	US- 5,965,697	10-12-1999	Czaplewski <i>et al.</i>	All
	U3	US-2005/0053603 A1	03-10-2005	Egashira <i>et al.</i>	All
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
/I.D./	F1		EP 1 325 751 A1	07-09-2003	Daiichi Pharm. Co. Ltd.	All
↓	F2		WO 03/051921 A1	06-26-2003	Applied Research Systems, ARS Holding N.V.	All
	F3		WO 02/028419 A2	04-11-2002	Applied Research Systems, ARS Holding N.V.	All
	F4		WO 98/013495 A1	04-02-1998	British Biotech Pharm., <i>et al.</i>	All
↓	F5		WO 96/38559 A1	12-05-1996	Dana Farber Cancer Inst. Inc.	All
	F6		WO 02/30464	04-18-2002	Daiichi Seiyaku Co.	All
	F7					
	F8					
	F9					

Examiner Signature	/Ian Dang/	Date Considered	10/16/2007
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/540,234	
			Filing Date	June 21, 2005	
			First Named Inventor	Amanda Proudfoot	
			Group Art Unit	Unknown 1647	
			Examiner Name	unknown Ian Dang	
Sheet	2	of	2	Attorney Docket Number	ARS-108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.D./	R1	Database WPI, Section Ch, Week 200242, ACCESSION NO. 2002-394437, XP002238282, April 18, 2002.	
	R2	LAURENCE, J. S. <i>et al.</i> "Importance of basic residues and quaternary structure in the function of MIP-1beta: CCR5 binding and cell surface sugar interactions" <i>Biochemistry</i> , April 24, 2001, pp. 4990-4999, Vol. 40, No. 16.	
	R3	KOOPMANN, W. <i>et al.</i> "Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1-alpha" <i>Journal of Biological Chemistry</i> , April 11, 1997, pp. 10103-10109, Vol. 272, No. 15.	
	R4	FISHER, N.C. <i>et al.</i> "Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease" <i>Gut</i> , 1999, pp. 416-420, Vol. 45, No. 3.	
	R5	MIYAGUCHI, S. <i>et al.</i> "Elevated plasma RANTES in primary biliary cirrhosis patients" <i>Hepatology Research</i> , 1997, pp. 156-163, Vol. 8, No. 3.	
	R6	AJUEBOR, M. <i>et al.</i> "Novel protective effects of the CC chemokine CCL2/MCP-1 in concanavalin A-induced acute hepatitis" <i>Gastroenterology</i> , April 2002, pg. A-637, Vol. 122, No. 4, Suppl.1, abstract only.	
	R7	AJUEBOR, M. <i>et al.</i> "The coordinated action of CC chemokines and their receptors may orchestrate hepatic inflammation during chronic experimental cholangitis" <i>Gastroenterology</i> , July 2002, pg. 57, Vol. 123, No. 1, Suppl., abstract only.	
	R8	AJUEBOR, M. <i>et al.</i> "CCL3/MIP-1 alpha, a crucial chemokine in the pathogenesis of T-cell mediated hepatitis in mice" <i>Biosis</i> , March 2003, pp. 1-2, XP002263040.	
✓	R9	PROUDFOOT, A. E. I. <i>et al.</i> "Strategies for chemokine antagonists as therapeutics" <i>Seminars in Immunology</i> , 2003, pp. 57-65, Vol. 15, No. 1.	
	R10		
	R11		
	R12		
	R13		

Examiner Signature	/Ian Dang/	Date Considered	10/16/2007
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.